The deal comes just weeks after Paris-based LimFlow won FDA premarket approval (PMA) for its breakthrough system to treat chronic limb-threatening ischemia (CLTI).
San Jose, California–based Inari said it expects to complete the acquisition by the end of 2023. Inari will pay $250 million in cash at closing, plus up to $165 million based on certain commercial and reimbursement milestones.
Medical Design & Outsourcing: How LimFlow’s foot-saving system prevents amputations in patients with no other options
Inari CEO Drew Hykes said the LimFlow acquisition “is closely aligned …